The new generation of antipsychotic drugs

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 2, 1996, Pages 73-76

  Tamminga, C A ^a   Lahti, A C ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Clinical response; Neuroleptics; New antipsychotics; Olanzapine; Seroquel; Sertindole; Ziprazidone

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

CONFERENCE PAPER; DRUG EFFICACY; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; HUMANS; IMIDAZOLES; INDOLES; PIPERAZINES; PIRENZEPINE; SCHIZOPHRENIA; THIAZOLES;

EID: 0029890025     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199605002-00012     Document Type: Conference Paper

References (15)

1. Arvanitis LA (1995) Seroquel (ICI 204,636), a new 'atypical' antipsychotic: overview of clinical development. In American College of Neuropsychopharmacology (ACNP) meeting, December 1995, San Juan, Puerto Rico. Washington, DC: American College of Neuropsychopharmacology.
2. Beasley CM, Tollefson G, Tran P, et al. (1996) Olanzapine versus placebo and haloperidol. Neuropsychopharmacology 14:111-123.
3. Bymaster FP, Zalligaro DO, Falcone JF, et al. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
4. Fleischhacker WW, Link CCG, Home B (1995) A multicenter, double-blind, randomized comparison of dose and dose regimen of 'Seroquel' in the treatment of patients with schizophrenia. In American College of Neuropsychopharmacology (ACNP) meeting, December 1995, San Juan, Puerto Rico. Washington, DC: American College of Neuropsychopharmacology.
5. Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Seroquel: Electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 112:293-298.
6. Kane J, Honigfeld G, Singer J, et al. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
7. Lahti AC, Lahti RA, Tamminga CA (1996) New neuroleptics and experimental antipsychotics: future roles. In Advances in Neuroleptic Drugs. Washington, DC: American Psychiatric Association Press; pp 57-87.
8. Martin PT, Grebb JA, Schmitz PJ, et al. (1994) Efficacy and safety of sertindole in double-blind, placebo-controlled trials of schizophrenic patients [abstract]. Schizophr Res 11:107.
9. Robertson GS, Fibiger HC (1996) Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology 14:105-110.
10. 2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analog 3,4-methylenedioxymethamphetamine. J Neurochem 62:1382-1389.
11. Skarsfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281:289-294.
12. Skarsfeldt T, Perregaard J (1990) Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurons in rat. Eur J Pharmacol 182:613-614.
13. Tamminga CA, Gerlach J (1987) New neuroleptics and experimental antipsychotics in schizophrenia. In Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York: Raven Press; pp 1129-1140.
14. Tamminga CA, Cascella N, Fakouhi TD, et al. (1992a) Enhancement of NMDA-mediated transmission in schizophrenia. In Novel Antipsychotic Drugs. Edited by Meltzer HY. New York: Raven Press; pp 171-177.
15. Tamminga CA, Cascella NG, Lahti RA, et al. (1992b) Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm 88:165-175.